The present invention relates to linkers, which contain amide surrogates with a regular or a novel lysosomal enzymatic cleavable dipeptidic unit, for connecting cytotoxic drugs to antibodies. The present invention also relates to ADCs (antibody-drug conjugates) derived from these amide surrogate linkers for the treatment of cancers.本發明涉及一類連接細胞毒素藥物與抗體,包含可被常規或新型可被溶酶體酶溶解的二肽結構單元取代的醯胺的連接體。本發明也公開了這類氨基取代的連接體的衍生物ADCs(抗體-藥物偶聯物)在治療癌症中的應用。